Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This entry describes a combination of four distinct antibiotics: ceftriaxone, gentamicin, cefuroxime, and ciprofloxacin. While these agents are not typically formulated into a single product or administered simultaneously as a routine regimen, they are often used in various combinations or sequentially to treat a broad range of bacterial infections, especially those involving multiple or resistant pathogens. * **Ceftriaxone:** A third-generation cephalosporin, broad-spectrum, with excellent penetration into meninges, eyes, and inner ear. Has a long half-life allowing for daily or twice-daily dosing. Effective against many gram-negative bacteria, including MDR Enterobacteriaceae, but less active against MSSA [2]. Efficacy correlates with bacterial growth rate [1]. * **Gentamicin:** An aminoglycoside antibiotic effective against many gram-negative bacteria. Often used for synergistic effects with other antibiotics. Like ceftriaxone, shows better efficacy against rapidly growing bacteria [1]. Dosing is weight-based and requires monitoring due to potential toxicity. * **Cefuroxime:** A second-generation cephalosporin, resistant to beta-lactamase, with broad-spectrum activity against gram-positive and gram-negative organisms. Used for respiratory, skin, urinary tract infections, gonorrhea, and early Lyme disease [5]. * **Ciprofloxacin:** A fluoroquinolone antibiotic with broad-spectrum activity against gram-negative and some gram-positive bacteria. Less dependent on bacterial growth rate than ceftriaxone or gentamicin [1]. Maintains significant bacterial load reduction even during slow bacterial growth [1]. Combinations involving these antibiotics are used for various infections, including complicated UTIs/pyelonephritis, severe respiratory infections, bacteremia, and infections where broad empirical coverage is needed or specific resistant pathogens are suspected.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ceftriaxone + Gentamicin + Cefuroxime + Ciprofloxacin.